Austin Gurney

Summary

Publications

  1. pmc Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors
    Austin Gurney
    OncoMed Pharmaceuticals, Redwood City, CA 94063, USA
    Proc Natl Acad Sci U S A 109:11717-22. 2012
  2. pmc Anti-DLL4, a cancer therapeutic with multiple mechanisms of action
    Austin Gurney
    OncoMed Pharmaceuticals, 800 Chesapeake Drive, Redwood City, California 94063, USA
    Vasc Cell 3:18. 2011
  3. doi request reprint Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations
    Marcus Fischer
    OncoMed Pharmaceuticals, Inc, Redwood City, California 94063, USA
    Cancer Res 71:1520-5. 2011
  4. doi request reprint Targeting notch signaling with a notch2/notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency
    Wan Ching Yen
    OncoMed Pharmaceuticals, Inc, Redwood City, California
    Clin Cancer Res 21:2084-95. 2015
  5. doi request reprint Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells
    Wan Ching Yen
    OncoMed Pharmaceuticals Inc, Redwood City, CA, USA
    Clin Cancer Res 18:5374-86. 2012
  6. doi request reprint DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency
    Timothy Hoey
    OncoMed Pharmaceuticals Inc, Redwood City, CA 94063, USA
    Cell Stem Cell 5:168-77. 2009

Collaborators

Detail Information

Publications6

  1. pmc Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors
    Austin Gurney
    OncoMed Pharmaceuticals, Redwood City, CA 94063, USA
    Proc Natl Acad Sci U S A 109:11717-22. 2012
    ....
  2. pmc Anti-DLL4, a cancer therapeutic with multiple mechanisms of action
    Austin Gurney
    OncoMed Pharmaceuticals, 800 Chesapeake Drive, Redwood City, California 94063, USA
    Vasc Cell 3:18. 2011
    ..Preclinical studies have highlighted that both anti-CSC and anti-angiogenic activities contribute to its anti-tumor efficacy, and have supported the clinical development of anti-DLL4 antibody for the treatment of cancer...
  3. doi request reprint Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations
    Marcus Fischer
    OncoMed Pharmaceuticals, Inc, Redwood City, California 94063, USA
    Cancer Res 71:1520-5. 2011
    ..Our findings provide a rationale for targeting DLL4-Notch signaling for improved treatment of CRC patients with activating KRAS mutations...
  4. doi request reprint Targeting notch signaling with a notch2/notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency
    Wan Ching Yen
    OncoMed Pharmaceuticals, Inc, Redwood City, California
    Clin Cancer Res 21:2084-95. 2015
    ..Dysregulation of Notch signaling has been reported in several human tumor types. In this report, we describe the development of an antibody, OMP-59R5 (tarextumab), which blocks both Notch2 and Notch3 signaling...
  5. doi request reprint Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells
    Wan Ching Yen
    OncoMed Pharmaceuticals Inc, Redwood City, CA, USA
    Clin Cancer Res 18:5374-86. 2012
    ..In this report, we have extended these studies to pancreatic cancer and probed the mechanism of action in tumor and stromal cells involved in antitumor efficacy...
  6. doi request reprint DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency
    Timothy Hoey
    OncoMed Pharmaceuticals Inc, Redwood City, CA 94063, USA
    Cell Stem Cell 5:168-77. 2009
    ....